[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
Gilead told Reuters he thought the WHO research data was contradictory, hasty, and that previous research had already confirmed the drug’s benefits.
According to a WHO report on Thursday, their study called Solidarity showed that remdesivir had little or no effect on the duration and mortality of hospitalization of respiratory patients with Covid-19 during the 28-day study period. This antiviral drug is one of those used to treat the coronavirus infection of the president of the United States, Donald Trump. Previous research has shown that it reduces recovery time.
The WHO conducted the study with 11,266 adult patients from more than 30 countries. The evidence received was convincing, the world organization said.
According to Gilead, other studies of remdesivir, including one that compared it to placebo in 1,062 patients, showed that the treatment reduced the time it took to recover from Covid-19.
Data published by the WHO is inconsistent, while strong evidence from studies in peer-reviewed, peer-reviewed and peer-reviewed scientific journals supports the clinical efficacy of remdesivir, the company said.
According to Gilead, it is unclear whether a decisive conclusion can be drawn from the WHO research, as there were “differences” in the way the tests were conducted at each site and between the patients who received the drug. In April, Anthony Fauci, a leading infectious disease specialist from the US, predicted that remdesivir would be the standard treatment.
Pharmaceutical companies are searching for a cure for Covid-19 at a rapid pace. The new coronavirus pandemic has so far killed nearly 1.1 million people, with nearly 39 million confirmed infections, according to the Johns Hopkins University data collection portal.
Remdesivir has been developed to treat Ebola, which spreads fever, bleeding, vomiting, and diarrhea in human body fluids. The WHO Solidarity series of tests also looked at other active substances (hydroxychloroquine, anti-AIDS lopinavir / ritonavir and interferon) and found that they had little effect on patient survival and reduced hospital stays. Gilead called the results of Solidaridad’s investigation hasty because they had not yet been verified by scientists.
The United States Food and Drug Administration (FDA) issued an emergency license for remdesivir on May 1, which has been approved in several other countries around the world. Studies of hydroxychloroquine and lopinavir / ritonavir in the Solidarity research were stopped in June because they were ineffective, but studies of the Gilead drug, remdesivir, and interferon continued at more than 500 hospitals in more than 30 countries. On Friday, WHO responded to a Gilead statement in which the company criticized Solidarity’s methodology.
The result is reliable, do not let them claim anything else because there will be those who will try. Any benefit from remdesivir is likely to be accidental.
Richard Peto, an independent statistician who was asked by the WHO to evaluate Solidaridad’s results, told reporters.
Cover image source: MTI / Zsolt Czeglédi
[ad_2]
